Clarity Pharmaceuticals begins phase II trial using SAR-Bombesin as prostate cancer diagnostic

Clarity Pharmaceuticals (ASX: CU6) has begun its phase II diagnostic trial for patients with prostate cancer using its Copper-64 SAR-Bombesin product in imaging scans.

Related Keywords

China ,Mexico ,Australia ,Japan ,Sydney ,New South Wales ,Alan Taylor ,Jeffrey Norenberg ,Louise Emmett ,Australia Therapeutic Goods Administration Special Access Scheme ,Clarity Pharmaceuticals ,University Of New Mexico Health Sciences Centre ,Radiopharmaceutical Sciences ,Prof Louise Emmett ,Therapeutic Goods Administration ,Special Access Scheme ,Prof Emeritus ,Critical Care Medicine ,New Mexico ,Health Sciences ,